Vimarsana
Biggest News Aggregation in the World

Andy Plump News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Andy Plump. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Andy Plump Today - Breaking & Trending Today

Longwood Healthcare Leaders Spring MIT to Convene Life Science Thought Leaders at MIT Koch Institute - Vimarsana News

Longwood Healthcare Leaders Spring MIT to Convene Life Science Thought Leaders at MIT Koch Institute

Published: May 23, 2024

BOSTON, MA / ACCESSWIRE / May 23, 2024 / Longwood Fund, an early-stage life science venture firm, will convene top biopharmaceutical leaders for two days of discussion and networking at its annual Longwood

Source: finanznachrichten.de
Related Topics:
Dana Farber Cancer InstituteUnited StatesJake AuchinclossSally KornbluthArielle JacksonPeter MarksBrian GoffStephen HogeLaurie GlimcherDeborah DunsireAnne KlibanskiChristophe WeberAl SandrockMikael DolstenRochelle WalenskyChris ViehbacherMathai MammenBob LangerBob Langer CoPhil Sharp CoKoch Institute Professors Phil SharpKoch InstituteLongwood FundLongwood Healthcare Leaders SpringPhil Sharp
Immunology | BioPharma Dive - Vimarsana News

Immunology | BioPharma Dive

Published: May 16, 2024

BioPharma

Source: biopharmadive.com
Related Topics:
United StatesBristol Myer HirawatArtiva BiotherapeuticsGeorg SchettVictor BultoWilliam BlairCarlo RizzutoBen FidlerAstrazeneca SaphneloBristol MyersSamit HirawatBristol Myers SquibbUniversity Of PennsylvaniaDrug AdministrationNational Institutes Of HealthLupus Foundation Of AmericaFriedrich Alexander UniversityCarl JuneAndy PlumpTakeda PharmaceuticalLupus FoundationAurinia Pharmaceutical LupkynisNew England JournalMyer HirawatKyverna Therapeutics
Takeda speeds narcolepsy drug to late-stage testing - Vimarsana News

Takeda speeds narcolepsy drug to late-stage testing

Published: February 9, 2024

BioPharma

Source: biopharmadive.com
Related Topics:
Jazz PharmaceuticalsTakeda PharmaceuticalWall StreetAndy PlumpUmer RaffatClinical Trials
CAR-T for lupus: the 'tip of the iceberg' for cell therapy in autoimmune disease - Vimarsana News

CAR-T for lupus: the 'tip of the iceberg' for cell therapy in autoimmune disease

Published: January 30, 2024

BioPharma

Source: biopharmadive.com
Related Topics:
United StatesSamit HirawatArtiva BiotherapeuticsBristol MyersBristol Myer HirawatVictor BultoCarlo RizzutoAstrazeneca SaphneloGeorg SchettWilliam BlairUniversity Of PennsylvaniaLupus Foundation Of AmericaBristol Myers SquibbFriedrich Alexander UniversityNational Institutes Of HealthDrug AdministrationCarl JuneAndy PlumpTakeda PharmaceuticalLupus FoundationAurinia Pharmaceutical LupkynisNew England JournalMyer HirawatKyverna TherapeuticsNational Institutes
Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting - Vimarsana News

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Published: November 7, 2023

− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 1 − TAK-279...

Source: marketscreener.com
Related Topics:
United StatesSan DiegoNew OrleansUnited KingdomAlan KivitzGreenwood CarrieroExchange CommissionResearch DevelopmentHealth Technology AssessmentJournals LibraryAmerican College Of RheumatologyAmerican Academy Of Dermatology Annual MeetingTakeda Pharmaceutical Company LimitedArthritis FoundationSociety For Investigative Dermatology Annual MeetingTakeda PharmaceuticalsAmerican CollegePsoriasis AreaSeverity IndexPhysician Global AssessmentAndy PlumpPsoriatic ArthritisTyrosine KinaseAnnual ReportDermatology Annual